Literature DB >> 19528422

Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome.

Denise K Woo1, Christopher R Jones, Monique N Vanoli-Storz, Sabine Kohler, Sunil Reddy, Ranjana Advani, Richard T Hoppe, Youn H Kim.   

Abstract

OBJECTIVES: To identify prognostic factors in primary cutaneous anaplastic large cell lymphoma (pcALCL), focusing on extensive limb disease (ELD), defined as initial presentation or progression to multiple skin tumors in 1 limb or contiguous body regions, and to study gene expression profiles of patients with pcALCL.
DESIGN: Retrospective cohort study.
SETTING: The Stanford Comprehensive Cancer Center and dermatology ambulatory clinics. PATIENTS: A total of 48 patients with pcALCL evaluated from 1990 through 2005. MAIN OUTCOME MEASURES: Hazard ratios (HRs) for prognostic factors for overall survival (OS) and disease-specific survival (DSS) and risk factors for progression to extracutaneous disease were identified using Cox regression. Gene expression profiles of 9 typical pcALCL and 3 ELD samples were investigated using complementary DNA microarrays.
RESULTS: Univariate analysis demonstrated age, ELD, and progression to extracutaneous disease as significant prognostic factors for OS, whereas ELD and progression to extracutaneous disease were significant for DSS. In multivariate analysis, age (HR, 1.83; 95% confidence interval [CI], 1.02-3.26) and progression to extracutaneous disease (HR, 6.42; 95% CI, 1.39-29.68) remained significant for OS, whereas ELD (HR, 29.31; 95% CI, 1.72-500.82) and progression to extracutaneous disease (HR, 13.12; 95% CI, 1.03-167.96) remained independent prognostic factors for DSS. Presentation with T3 disease was a risk factor for progression to extracutaneous disease (HR, 10.20; 95% CI, 1.84-56.72). Microarray data revealed that patients with ELD and typical pcALCL formed distinct clusters.
CONCLUSIONS: Patients with ELD have a more aggressive course associated with a differential gene expression profile. More aggressive treatments may be indicated for patients with ELD and those whose disease progresses to extracutaneous disease because they have poorer outcomes.

Entities:  

Mesh:

Year:  2009        PMID: 19528422     DOI: 10.1001/archdermatol.2009.74

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  16 in total

1.  A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period.

Authors:  Masataka Hosoi; Motoshi Ichikawa; Yoichi Imai; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2010-10-26       Impact factor: 2.490

Review 2.  Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides.

Authors:  Meenal Kheterpal; Neha Mehta-Shah; Pooja Virmani; Patricia L Myskowski; Alison Moskowitz; Steven M Horwitz
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

Review 3.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

Review 4.  Breast implant-associated ALCL: a unique entity in the spectrum of CD30+ lymphoproliferative disorders.

Authors:  Sara K Story; Michael K Schowalter; Larisa J Geskin
Journal:  Oncologist       Date:  2013-02-21

5.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

6.  Radiotherapy in cutaneous anaplastic large cell lymphoma.

Authors:  Raj Hegde
Journal:  J Cutan Aesthet Surg       Date:  2010-01

7.  Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: An International Lymphoma Radiation Oncology Group Multi-institutional Experience.

Authors:  Lynn Million; Esther J Yi; Frank Wu; Rie Von Eyben; Belinda A Campbell; Bouthaina Dabaja; Richard W Tsang; Andrea Ng; Lynn D Wilson; Umberto Ricardi; Youlia Kirova; Richard T Hoppe
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-24       Impact factor: 7.038

8.  Diffuse Primary Cutaneous Anaplastic Large Cell Lymphoma Treated by Rotational Total Skin Electron Beam Radiotherapy with Custom Shielding: Case Report.

Authors:  Alexander D Sherry; George X Ding; Austin N Kirschner
Journal:  J Med Imaging Radiat Sci       Date:  2019-06-15

9.  A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma.

Authors:  Wen-Tian Lyu; Qi-Bin Song; Wang Qiong; Jing Liu; Ren Yong; Feng-Tao Yi; Dong-Liang Han
Journal:  Medicine (Baltimore)       Date:  2021-05-07       Impact factor: 1.889

10.  Treatment of primary cutaneous anaplastic large cell lymphoma with superficial x-rays.

Authors:  Malene E Jepsen; Robert Gniadecki
Journal:  Dermatol Reports       Date:  2015-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.